GSK_Annual_Report_2021

Annual Report 2020-21 97 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 C. CASH FLOWS FROM FINANCING ACTIVITIES Repayments of borrowings (15.30) (40.60) Interest paid, other than on lease liabilities (34.99) (82.83) Interest paid on lease liabilities (3,18.15) (3,28.53) Principal payment of lease liabilities (14,83.08) (14,64.60) Dividend paid to company's shareholders (677,62.41) (338,81.21) Tax on distributed profit - (69,64.38) Net cash outflow from financing activities C (696,13.93) (427,62.15) Net increase in cash and cash equivalents (A + B + C) 306,87.41 24.91 Cash and cash equivalents at the beginning of the year 98,02.79 97,77.88 Cash and cash equivalents at the end of the year 404,90.20 98,02.79 Net increase in cash and cash equivalents 306,87.41 24.91 NOTES: Cash and cash equivalents include: Balances with banks Current accounts 205,83.20 28,60.85 Term deposits with original maturity period of less than three months 199,07.00 6,00.00 Cheques on hand - 63,41.94 Total 404,90.20 98,02.79 The above Standalone Cash Flow Statement has been prepared under the “Indirect Method” as set out in Ind AS - 7 ‘Statement of Cash Flows’ Standalone Cash Flow Statement for the year ended March 31, 2021 In terms of our report attached For Deloitte Haskins & Sells LLP For and on behalf of the Board of Directors Chartered Accountants R. S. Karnad Chairperson DIN: 00008064 S. Venkatesh Managing Director DIN: 07263117 Rupen K. Bhatt P. Thakur CFO & Whole-time Director DIN: 07971789 Partner D. Sundaram Audit Committee Chairman DIN: 00016304 A. Nadkarni Company Secretary FCS 10460 Mumbai, May 18, 2021 Mumbai, May 18, 2021